RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology related deals dominate the landscape
Biotech companies in U.S. awarded largest sums of capital, followed by Mainland China and UK
LONDON, March 14, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of a new report, Biopharma deals in review: Review of an extraordinary 2021 and expectations for the future Biopharma Deals, which highlights emerging market trends and features detailed analysis of the key deals of 2021 and potential implications for 2022. This year's report finds RNA, cell & gene therapies, AI, CRISPR and oncology related deals dominated the landscape in 2021. In addition, U.S. biotech companies raised the majority of capital followed by Mainland China and the UK.
While the volume of biotech investments has lessened, 2021 was yet another extraordinary year for biopharma deal-making. Trends driving licensing, collaborations and joint ventures included: a maturation of deals toward co-development and co-commercialization, the increasingly global nature of deal-making, continued energy around oncology therapeutics and pharma companies seeking footholds within the enabling technologies underpinning next-generation treatments.
As the COVID-19 pandemic evolves to become endemic, life science industries will continue to assess the changing drug development landscape. Emerging trends suggest innovators and investors will drive the next great advances in human health. This year's Biopharma Deals report findings, include:
Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership, Clarivate: "The desire to develop innovative medicines that will deliver better and more robust health outcomes for patients will continue to be a key driver for biopharma deal-making activity. While pharma companies will still look to acquire potential blockbuster treatments to replace existing products that are losing patent protection, others are urgently seeking inroads to the enabling technologies being developed by biotechs, such as gene and cell therapies, genome-editing, antibody-drug conjugates, RNA technologies and AI/ML applications, which are expected to underpin the next generation of transformative blockbusters."
Clarivate is committed to supporting customers across the entire drug, device and medical technology lifecycles to advance, create and protect innovation. By combining patient journey data, therapeutic area expertise, artificial intelligence and analytics in ways that unlock hidden insights, data-driven decisions and accelerate innovation, Clarivate's end-to-end research intelligence is designed to enable customers to make informed evidence-based decisions and better understand the changing landscape.
The full Biopharma Deals Report can be accessed here.
Join the conversation, use hashtag #BioPharmaDeals2022 and mention Clarivate for Life Sciences & Healthcare on Twitter and LinkedIn.
Methodology for the Report
Clarivate technology and experts harmonize billions of datapoints from thousands of sources and provide a unified view to drive decision-making for a variety of use cases, including deal-making, forecasting, portfolio strategy and more. Leveraging data and insights from BioWorld™ and Cortellis Deals Intelligence™, as well as a proprietary, predictive analytics which draw on more than 20 traits from across the entire body of Cortellis data, including 110,000+ life sciences deals, 36,000+ contracts and 9,500+ unredacted contracts, Clarivate drew upon technology and expertise to harmonize datapoints from multiple sources to provide a unified view of deal-making in 2021 and potential implications.
To learn more about Clarivate data products, visit www.clarivate.com.
About Clarivate
Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world's most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.
Media Contact
Catherine Daniel
Director, External Communications, Life Sciences & Healthcare
media.enquiries@clarivate.com
1 Source: Biopharma deals in review: a look back at an energetic H1 and what to expect next. Clarivate, [online], Available at: https://clarivate.com/lp/biopharma-deals-in-review/. (accessed on February 21, 2022).
2 Carey, K. Deals reach a record $213.5B, as M&As in 2021 struggle (January 12, 2022). BioWorld, [online], Available at: https://www.bioworld.com/articles/515071-deals-reach-a-record-2135b-as-m-and-as-in-2021-struggle. (accessed on February 21, 2022).
3 Source: BioWorld; Cortellis Deals Intelligence
4 Source: BioWorld; Cortellis Deals Intelligence